A review.The consensus group to consider the use of biol. agents in the treatment of rheumatic diseases, which consisted of rheumatologists from different countries worldwide, met during the 11th Annual Workshop on Advances in Targeted Therapies.In view of the new data for abatacept, B-cell-specific agents, interleukin 1 receptor antagonists, tocilizumab, and tumor necrosis factor α blocking agents, an update of the previous consensus statement is appropriate.It is hoped that this updated consensus statement, which is based on the best evidence available at this time and is modified by expert opinion, will facilitate the optimal use of these agents for patients with conditions approved by the FDA or EMEA (European Medicines Agency) for clin. use.Extensive tables of the use of these agents in non-registered uses are included as appendices, to help experienced doctors to use these drugs in exceptional ('off-label') circumstances.